Haddjeri N, Blier P, de Montigny C
Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:11-7. doi: 10.1097/00004850-199512004-00003.
Mirtazapine (Org 3770, Remeron) is a new alpha2-adrenoceptor antagonist which is an effective antidepressant drug. An in vivo electrophysiological paradigm in the rat was used to assess the effects of acute and long-term treatment with mirtazapine on pre- and postsynaptic alpha2-adrenoceptors and to determine whether this drug can modulate serotonin (5-HT) neurotransmission. The acute administration of mirtazapine produced a rapid increase in both noradrenaline and 5-HT neurotransmission by blocking both alpha2-adrenergic auto- and heteroreceptors, resulting in an enhanced tonic activation of postsynaptic 5-HT receptors. Long-term administration showed that this tonic activation of postsynaptic 5-HT receptors was most likely enhanced after such a treatment, as a result of a sustained increase in 5-HT neuronal activity in the presence of and due to inactivated alpha2-adrenergic heteroreceptors.
米氮平(Org 3770,瑞美隆)是一种新型α2-肾上腺素能受体拮抗剂,是一种有效的抗抑郁药物。采用大鼠体内电生理模型来评估米氮平急性和长期治疗对突触前和突触后α2-肾上腺素能受体的影响,并确定该药物是否能调节5-羟色胺(5-HT)神经传递。急性给予米氮平通过阻断α2-肾上腺素能自身受体和异源受体,使去甲肾上腺素和5-HT神经传递迅速增加,导致突触后5-HT受体的紧张性激活增强。长期给药表明,由于在α2-肾上腺素能异源受体失活的情况下5-HT神经元活性持续增加,这种突触后5-HT受体的紧张性激活在该治疗后很可能增强。